Table 2.

Grade 3–4 adverse effects

	Phase I			Phase II
	Dose level 1	Dose level 2	Dose level 3	RS	CLL
No. of patients (%)	3 (25)	6 (50)	3 (25)	30 (33)	60 (67)
Hematologic
Neutropenia	2 (67)	5 (83)	3 (100)	25 (89)	46 (77)
Anemia	1 (33)	3 (50)	1 (33)	15 (50)	29 (48)
Thrombocytopenia	3 (100)	6 (100)	3 (100)	23 (77)	49 (82)
Non-hematologic
Neutropenic fever		2(33)	1(33)	6 (20)	6 (10)
Non-neutropenic fever					3 (5)
Dehydration				1 (3)	6 (10)
Fatigue					1 (2)
Infection		3(50)	1(33)	5 (17)	12 (20)
Diarrhea		1(17)		1 (3)	2 (3)
Nausea/vomiting				2 (6)	4 (6)
Hemorrhage				1 (3)	2 (3)
Dyspnea				3 (9)
ARDS					1 (2)
Airway obstruction				1 (3)
Atrial fibrillation				1 (3)
Hypotension				1 (3)	1 (2)
Acute renal failure					1 (3)
Altered mental status				1 (3)
Syncope				1 (3)
Tumor lysis syndrome					2 (3)
Multiorgan failure					1 (2)
Hyperglycemia					1 (2)

Abbreviations: ARDS = Adult Respiratory Distress Syndrome